Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines (R) Insights Hodgkin Lymphoma, Version 1.2018 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Armand, P., Bello, C. M., Benitez, C. M., Bierman, P. J., Chen, R., Dabaja, B., Dean, R., Forero, A., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Hochberg, E. P., Huang, J., Johnston, P. B., Kaminski, M. S., Kenkre, V. P., Khan, N., Maddocks, K., Maloney, D. G., Metzger, M., Moore, J. O., Morgan, D., Moskowitz, C. H., Mulroney, C., Rabinovitch, R., Seropian, S., Tao, R., Winter, J. N., Yahalom, J., Burns, J. L., Ogba, N. 2018; 16 (3): 245–54

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN Guidelines Panel meets at least annually to review comments from reviewers within the NCCN Member Institutions, examine relevant data, and reevaluate and update the recommendations. These NCCN Guidelines Insights summarize recent updates centered on treatment considerations for relapsed/refractory classic HL.

View details for DOI 10.6004/jnccn.2018.0013

View details for Web of Science ID 000427032100007

View details for PubMedID 29523663